Literature DB >> 22864855

Right ventricular pulmonary hypertension.

Marco Guazzi1, Serenella Castelvecchio, Francesco Bandera, Lorenzo Menicanti.   

Abstract

In heart failure (HF) syndrome, the development of pulmonary hypertension (PH), right ventricular (RV) dysfunction and failure are ominous prognostic signs. Pathophysiology, clinical interest and targeted therapeutic approaches for left-sided PH and its consequences on RV function have been traditionally confined to advanced HF stages. Community- and population-based studies have clearly indicated that PH is frequent even in HF patients with preserved ejection fraction, and may carry important prognostic implications in normal ageing as well. HF guidelines are inconclusive on both preventive and curative strategies for left-sided PH and its consequences on RV function. The search for new therapeutic opportunities targeted on pulmonary vascular and right heart remodeling are an important challenge for the future.

Entities:  

Mesh:

Year:  2012        PMID: 22864855     DOI: 10.1007/s11897-012-0106-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  58 in total

1.  Pulmonary capillary wedge pressure augments right ventricular pulsatile loading.

Authors:  Ryan J Tedford; Paul M Hassoun; Stephen C Mathai; Reda E Girgis; Stuart D Russell; David R Thiemann; Oscar H Cingolani; James O Mudd; Barry A Borlaug; Margaret M Redfield; David J Lederer; David A Kass
Journal:  Circulation       Date:  2011-11-30       Impact factor: 29.690

2.  Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

Authors:  Thomas F Lüscher; Frank Enseleit; Richard Pacher; Veselin Mitrovic; Matthias R Schulze; Roland Willenbrock; Rainer Dietz; Valentin Rousson; David Hürlimann; Sebastian Philipp; Thomas Notter; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

3.  Surgical ventricular restoration for advanced congestive heart failure: should pulmonary hypertension be a contraindication?

Authors:  Nishant D Patel; Jason A Williams; Lois U Nwakanma; Michele M Waldron; David A Bluemke; John V Conte
Journal:  Ann Thorac Surg       Date:  2006-09       Impact factor: 4.330

4.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

5.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

6.  Prostacyclin therapy in patients with congestive heart failure.

Authors:  Y Yui; H Nakajima; C Kawai; T Murakami
Journal:  Am J Cardiol       Date:  1982-08       Impact factor: 2.778

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 8.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

9.  Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone.

Authors:  Gregory D Lewis; Ravi V Shah; Paul P Pappagianopolas; David M Systrom; Marc J Semigran
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

10.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

View more
  3 in total

Review 1.  Treatment and Prognosis of Pulmonary Hypertension in the Left Ventricular Assist Device Patient.

Authors:  Christopher W Jensen; Andrew B Goldstone; Y Joseph Woo
Journal:  Curr Heart Fail Rep       Date:  2016-06

2.  Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension.

Authors:  Andres Rubiano; Yanfei Qi; Dominic Guzzo; Anandharajan Rathinasabapathy; Kyle Rowe; Carl Pepine; Chelsey Simmons
Journal:  J Mech Behav Biomed Mater       Date:  2015-12-19

Review 3.  RV diastolic dysfunction: time to re-evaluate its importance in heart failure.

Authors:  Richard G Axell; Stephen P Hoole; James Hampton-Till; Paul A White
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.